Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Safety of BCA101, an EGFR/TGFβ inhibitor, with pembrolizumab in HNSCC

Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH, provides an overview of findings from a dose expansion trial (NCT04429542) of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC). No additional toxicities were reported in the trial, and skin rashes associated with EGFR inhibition were manageable. Patients who were HPV-negative additionally had better responses. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.